Hosted on MSN34m
Gilead’s lenacapavir applications for HIV gain EMA validation
Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...
Morgan Stanley sees FDA approval of GILD's Lenacapavir
Investing.com -- Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ: GILD )' Lenacapavir (LEN) for HIV ...
stocknews23h
3 Pharmaceutical Stocks With Blockbuster Drug Potential
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Healio2h
Top in ID: Undetected bird flu cases in veterinarians; CDC officers remain in positions
Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...
manilatimes8h
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Ligand originated, structured, and invested $50 million and led a syndicate of co-investors who invested $25 million in ...
What Analysts Think of Salesforce Stock Ahead of Earnings
Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on the cloud-based software company's stock, anticipating AI-driven gains.
Zacks.com on MSN4h
4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty
The new year has been turbulent so far for the equity market, with geopolitical tensions and trade policies playing a significant role in shaping investor sentiment. Trump's tariff policies have not ...